- CEO
- Jie Zhang
- Full Time Employees
- 1,069
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Beijing China
- IPO Date
- Aug 16, 2021
- Business
- Sino Biological, Inc. is a global biotechnology company that specializes in the research, development, manufacture, and commercialization of life science research reagents and custom contract research services for biomedical research, therapeutic discovery, and in vitro diagnostics. Founded in 2007 and headquartered in Beijing, China, the company operates primarily across two business segments: biological reagents and technical contract services. Its core product portfolio comprises recombinant proteins, including cytokines, growth factors, viral antigens, immune checkpoint targets, receptor proteins, and enzymes; research-grade and diagnostic antibodies, including monoclonal antibodies, polyclonal antibodies, recombinant rabbit monoclonal antibodies, neutralizing antibodies, and matched antibody pairs; enzyme-linked immunosorbent assay kits and quantitative assay reagents; and molecular biology tools, including cDNA clones, transfection reagents, and cell culture media formulations. In addition, the company provides comprehensive contract research organization services, including custom recombinant protein expression and purification across mammalian, insect, and microbial host systems; custom hybridoma and recombinant antibody generation; antibody humanization and characterization; epitope binning and binding kinetics analysis; bioanalytical assay development; and pharmacokinetic and anti-drug antibody assay support. Sino Biological serves pharmaceutical and biotechnology companies, academic institutions, diagnostic manufacturers, and contract research organizations worldwide. The company maintains operational facilities, research laboratories, and distribution hubs across China, the United States, Germany, and Japan, distributing products to clients in more than 90 countries. In recent corporate developments, Sino Biological has executed strategic growth initiatives, including the acquisition of Canadian life science firm SignalChem Lifesciences to expand its active kinase, enzyme, and bioreagent product portfolios. The company has also strengthened its international footprint through the establishment of its Center for Bioprocessing and new innovation facilities in the United States, launched high-throughput artificial intelligence-assisted antibody engineering platforms, and formed strategic alliances with life science technology providers to broaden its global diagnostic and therapeutic research offerings.